contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


expres2ion-biotech-one-pager-early-phase-i-clinical-validation-of-es2b-c001-de-risks-near-term-development

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Equity Research Analyst

Philip Coombes

Head of Equities

Michael Friis

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics.

The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

ExpreS2ion Biotech Holding

We have published an updated one-pager on ExpreS2ion Biotech following early immunogenicity data and dose escalation clearance in the Phase I ES2B-C001 breast cancer vaccine, which begins to de-risk near-term development, alongside the completed TO 11 warrant programme. The note also reflects the malaria licensing agreement with Serum Institute of India, which provides platform validation and limited non-dilutive funding, while ES2B-C001 remains the core value driver.


We have published an updated one-pager on ExpreS2ion Biotech following encouraging early immunogenicity data and dose escalation clearance in the ongoing Phase I study of the HER2-targeted breast cancer vaccine ES2B-C001, which begins to de-risk near-term clinical development, as well as the completion of the TO 11 warrant programme. The note updates our assessment of the core value drivers, funding outlook and dilution, and revisits the market-implied probability of success. We also incorporate the recently signed malaria licensing agreement with Serum Institute of India, which provides platform validation and some non-dilutive funding, but has a more limited impact on total pipeline value relative to ES2B-C001.
You can also watch the presentation of the Q3 2025 results, where CEO Bent U. Frandsen and CFO Keith Alexander discuss recent developments and upcoming milestones, here: <a href="https://www.inderes.dk/videos/expres2ion-biotechnologies-presentation-of-q3-2025-earnings-release">https://www.inderes.dk/videos/expres2ion-biotechnologies-presentation-of-q3-2025-earnings-release</a> Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotech for a digitalIR/Corporate Visibility subscription agreement. / Philip Coombes 08:44 15/01/2026

HC Andersen Capital

<ul><li>ExpreS2ion Biotech har opdateret deres vurdering af ES2B-C001, efter positive tidlige immunogenicitetsdata og godkendelse af dosisoptrapning i fase I-studiet, hvilket reducerer risikoen for den nærmeste kliniske udvikling.</li><li>Virksomheden har afsluttet TO 11 warrant-programmet og indgået en malaria-licensaftale med Serum Institute of India, som giver platformvalidering og ikke-dilutiv finansiering.</li><li>Den nye aftale med Serum Institute har en begrænset indvirkning på den samlede pipelineværdi sammenlignet med ES2B-C001.</li><li>HC Andersen Capital modtager betaling fra ExpreS2ion Biotech for en digitalIR/Corporate Visibility abonnementsaftale.</li></ul>Dette indhold er genereret af AI. Du kan give feedback om det på Inderes <a href="https://forum.inderes.com/t/inderes-fi-sisallon-kehitysideat/71/last">forum</a>.

ExpreS2ion Biotech (One-pager): Early Phase I clinical validation of ES2B-C001 de-risks near term development

Summary